#BEGIN_DRUGCARD DB06822

# AHFS_Codes:
Not Available

# ATC_Codes:
B01AB10

# Absorption:
Subcutaneous injection - about 90% when measured as anti-Xa activity versus 67% for anti-IIa activity.

# Biotransformation:
Sulfation and polymerization occurs in the liver.

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
9041-08-1

# ChEBI_ID:
Not Available

# Chemical_Formula:
Not Available

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-14 10:21:14 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

# Dosage_Forms:
Injection	Parenteral
Injection	Parenteral

# Drug_Category:
Anticoagulants
Antithrombotics
Heparins

# Drug_Interactions:
Drotrecogin alfa	Low molecular weight heparins (LMWHs) such as tinzaparin may enhance the adverse/toxic effects of drotrecogin alfa. Bleeding may occur. The potential benefits of drotrecogin alfa should be weighed against the increased risk of bleeding in patients on therapeutic doses of LMWHs.

# Drug_Reference:
10348714	Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B: Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999 Jan;81(1):22-5.
11011803	Hedner U: Development of tinzaparin: a heparinase-digested low-molecular-weight heparin. Semin Thromb Hemost. 2000;26 Suppl 1:23-9.
11234669	Pautas E, Siguret V, d'Urso M, Laurent M, Gaussem P, Fevrier M, Durand-Gasselin B: [Monitoring of tinzaparin in a ten day treatment dose in elderly patients]. Rev Med Interne. 2001 Feb;22(2):120-6.
11556655	Fossler MJ, Barrett JS, Hainer JW, Riddle JG, Ostergaard P, van der Elst E, Sprogel P: Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Am J Health Syst Pharm. 2001 Sep 1;58(17):1614-21.
11849226	Cambus JP, Saivin S, Heilmann JJ, Caplain H, Boneu B, Houin G: The pharmacodynamics of tinzaparin in healthy volunteers. Br J Haematol. 2002 Mar;116(3):649-52.
14640933	Pineo GF, Hull RD: Tinzaparin in the treatment of venous thromboembolism. Expert Opin Pharmacother. 2003 Dec;4(12):2355-62.
15212562	Cheer SM, Dunn CJ, Foster R: Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs. 2004;64(13):1479-502.
20568836	Hoy SM, Scott LJ, Plosker GL: Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs. 2010 Jul 9;70(10):1319-47. doi: 10.2165/11203710-000000000-00000.
7528134	Friedel HA, Balfour JA: Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs. 1994 Oct;48(4):638-60.
9278462	Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997 Sep 4;337(10):663-9.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Herbs with anticoagulant/antiplatelet properties (ginger, gingko, garlic) may increase the risk of bleeding.

# GenBank_ID:
Not Available

# Generic_Name:
Tinzaparin

# HET_ID:
Not Available

# Half_Life:
Anti-Xa activity is 82 minutes. Anti-IIa activity is 71 minutes.

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
6828

# Mechanism_Of_Action:
Tinzaparin binds to the plasma protein antithrombin III, forming a complex with then accelerates the inhibition of factor Xa. Its affinity for factor Xa is 2-4 times greater than that of unbound ATIII. The inactivation of factor Xa in turn will exponentially generation of thrombin (factor IIa) molecules, which is needed to activate fibrinogen to fibrin. The coagulation cascade is inhibited because fibrin cannot be formed in the presence of tinzaparin. Like all LMWH, it cannot be given intramuscularly due to increased risk of hematoma.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
Not Available

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Tinzaparin, like other LMWHs, have a higher anti-Xa activity  than anti-IIa activity. The anti-Xa activity of tinzaparin is 2.0 +/- 0.5 times greater than its to anti-IIa activity. Heparin exhibits approximately equal inhibitory activity against Xa and IIa. Tinzaparin is an anticoagulant that blocks the formation of thrombi. Like all LMWHs, tinzaparin only causes activated partial thromboplastin time (aPTT) prolongation at higher doses and routine monitoring is not recommended. However, anti-factor Xa levels may be monitored in some conditions such as pregnancy and renal dysfunction. Its use should be avoided in patients with a creatinine clearance less than 20 mL/min. In these patients, unfractionated heparin should be used. Tinzaparin can be used in patients who have a creatinine clearance between 20-30 mL/min, giving it the highest safety threshold for use in renal failure patients compared to all the LMWHs.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB06822

# Protein_Binding:
Low protein binding compared to unfractionated heparin.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Osteoporosis with increasing duration of use, bleeding, alopecia, heparin induced thrombocytopenia (HIT). All of these adverse drug reactions occur less with LMWH compared to unfractionated heparin. Tinzaparin showed no toxic effects at doses up to 5 mg/kg in mice, rats, or dogs in standard acute, subacute, and chronic toxicity studies.

# Update_Date:
2012-01-18 15:53:40 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
Not Available

# Phase_1_Metabolizing_Enzyme_1_ID:
7237

# Phase_1_Metabolizing_Enzyme_1_Name:
A disintegrin and metalloproteinase with thrombospondin motifs 4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
Not Available

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
O75173

# Drug_Target_1_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15567452	Morris TA, Jacobson A, Marsh JJ, Lane JR: Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity. Thromb Res. 2005;115(1-2):45-51.
15767980	Florian-Kujawski M, Hoppensteadt D, Maddineni J, Ziegler H, Fareed J: Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications. Int Angiol. 2004 Dec;23(4):346-54.
19888521	Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S, Eisele G, Naggi A, Sasisekharan R, Torri G: Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost. 2009 Nov;102(5):865-73.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SERPINC1

# Drug_Target_1_GenBank_ID_Gene:
M21642

# Drug_Target_1_GenBank_ID_Protein:
179161

# Drug_Target_1_GeneCard_ID:
SERPINC1

# Drug_Target_1_Gene_Name:
SERPINC1

# Drug_Target_1_Gene_Sequence:
>1395 bp
ATGTATTCCAATGTGATAGGAACTGTAACCTCTGGAAAAAGGAAGGTTTATCTTTTGTCC
TTGCTGCTCATTGGCTTCTGGGACTGCGTGACCTGTCACGGGAGCCCTGTGGACATCTGC
ACAGCCAAGCCGCGGGACATTCCCATGAATCCCATGTGCATTTACCGCTCCCCGGAGAAG
AAGGCAACTGAGGATGAGGGCTCAGAACAGAAGATCCCGGAGGCCACCAACCGGCGTGTC
TGGGAACTGTCCAAGGCCAATTCCCGCTTTGCTACCACTTTCTATCAGCACCTGGCAGAT
TCCAAGAATGACAATGATAACATTTTCCTGTCACCCCTGAGTATCTCCACGGCTTTTGCT
ATGACCAAGCTGGGTGCCTGTAATGACACCCTCCAGCAACTGATGGAGGTATTTAAGTTT
GACACCATATCTGAGAAAACATCTGATCAGATCCACTTCTTCTTTGCCAAACTGAACTGC
CGACTCTATCGAAAAGCCAACAAATCCTCCAAGTTAGTATCAGCCAATCGCCTTTTTGGA
GACAAATCCCTTACCTTCAATGAGACCTACCAGGACATCAGTGAGTTGGTATATGGAGCC
AAGCTCCAGCCCCTGGACTTCAAGGAAAATGCAGAGCAATCCAGAGCGGCCATCAACAAA
TGGGTGTCCAATAAGACCGAAGGCCGAATCACCGATGTCATTCCCTCGGAAGCCATCAAT
GAGCTCACTGTTCTGGTGCTGGTTAACACCATTTACTTCAAGGGCCTGTGGAAGTCAAAG
TTCAGCCCTGAGAACACAAGGAAGGAACTGTTCTACAAGGCTGATGGAGAGTCGTGTTCA
GCATCTATGATGTACCAGGAAGGCAAGTTCCGTTATCGGCGCGTGGCTGAAGGCACCCAG
GTGCTTGAGTTGCCCTTCAAAGGTGATGACATCACCATGGTCCTCATCTTGCCCAAGCCT
GAGAAGAGCCTGGCCAAGGTGGAGAAGGAACTCACCCCAGAGGTGCTGCAGGAGTGGCTG
GATGAATTGGAGGAGATGATGCTGGTGGTCCACATGCCCCGCTTCCGCATTGAGGACGGC
TTCAGTTTGAAGGAGCAGCTGCAAGACATGGGCCTTGTCGATCTGTTCAGCCCTGAAAAG
TCCAAACTCCCAGGTATTGTTGCAGAAGGCCGAGATGACCTCTATGTCTCAGATGCATTC
CATAAGGCATTTCTTGAGGTAAATGAAGAAGGCAGTGAAGCAGCTGCAAGTACCGCTGTT
GTGATTGCTGGCCGTTCGCTAAACCCCAACAGGGTGACTTTCAAGGCCAACAGGCTTTTC
CTGGTTTTTATAAGAGAAGTTCCTCTGAACACTATTATCTTCATGGGCAGAGTAGCCAAC
CCTTGTGTTAAGTAA

# Drug_Target_1_General_Function:
Involved in serine-type endopeptidase inhibitor activity

# Drug_Target_1_General_References:
10361121	Bayston TA, Tripodi A, Mannucci PM, Thompson E, Ireland H, Fitches AC, Hananeia L, Olds RJ, Lane DA: Familial overexpression of beta antithrombin caused by an Asn135Thr substitution. Blood. 1999 Jun 15;93(12):4242-7.
11794707	Niiya K, Kiguchi T, Dansako H, Fujimura K, Fujimoto T, Iijima K, Tanimoto M, Harada M: Two novel gene mutations in type I antithrombin deficiency. Int J Hematol. 2001 Dec;74(4):469-72.
1547341	Blajchman MA, Fernandez-Rachubinski F, Sheffield WP, Austin RC, Schulman S: Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood. 1992 Mar 15;79(6):1428-34.
1555650	Olds RJ, Lane DA, Boisclair M, Sas G, Bock SC, Thein SL: Antithrombin Budapest 3. An antithrombin variant with reduced heparin affinity resulting from the substitution L99F. FEBS Lett. 1992 Apr 6;300(3):241-6.
1906811	Perry DJ, Daly M, Harper PL, Tait RC, Price J, Walker ID, Carrell RW: Antithrombin Cambridge II, 384 Ala to Ser. Further evidence of the role of the reactive centre loop in the inhibitory function of the serpins. FEBS Lett. 1991 Jul 22;285(2):248-50.
1977621	Daly M, Bruce D, Perry DJ, Price J, Harper PL, O'Meara A, Carrell RW: Antithrombin Dublin (-3 Val----Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS Lett. 1990 Oct 29;273(1-2):87-90.
2013320	Austin RC, Rachubinski RA, Blajchman MA: Site-directed mutagenesis of alanine-382 of human antithrombin III. FEBS Lett. 1991 Mar 25;280(2):254-8.
2126464	Mourey L, Samama JP, Delarue M, Choay J, Lormeau JC, Petitou M, Moras D: Antithrombin III: structural and functional aspects. Biochimie. 1990 Aug;72(8):599-608.
2229057	Gandrille S, Aiach M, Lane DA, Vidaud D, Molho-Sabatier P, Caso R, de Moerloose P, Fiessinger JN, Clauser E: Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine. J Biol Chem. 1990 Nov 5;265(31):18997-9001.
2365065	Borg JY, Brennan SO, Carrell RW, George P, Perry DJ, Shaw J: Antithrombin Rouen-IV 24 Arg----Cys. The amino-terminal contribution to heparin binding. FEBS Lett. 1990 Jun 18;266(1-2):163-6.
2781509	Erdjument H, Lane DA, Panico M, Di Marzo V, Morris HR, Bauer K, Rosenberg RD: Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thromb Res. 1989 Jun 15;54(6):613-9.
3080419	Chang JY, Tran TH: Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem. 1986 Jan 25;261(3):1174-6.
3162733	Erdjument H, Lane DA, Panico M, Di Marzo V, Morris HR: Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow. J Biol Chem. 1988 Apr 25;263(12):5589-93.
3179438	Devraj-Kizuk R, Chui DH, Prochownik EV, Carter CJ, Ofosu FA, Blajchman MA: Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Blood. 1988 Nov;72(5):1518-23.
3191114	Bock SC, Marrinan JA, Radziejewska E: Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry. 1988 Aug 9;27(16):6171-8.
3805013	Stephens AW, Thalley BS, Hirs CH: Antithrombin-III Denver, a reactive site variant. J Biol Chem. 1987 Jan 25;262(3):1044-8.
6298709	Bock SC, Wion KL, Vehar GA, Lawn RM: Cloning and expression of the cDNA for human antithrombin III. Nucleic Acids Res. 1982 Dec 20;10(24):8113-25.
6305982	Prochownik EV, Markham AF, Orkin SH: Isolation of a cDNA clone for human antithrombin III. J Biol Chem. 1983 Jul 10;258(13):8389-94.
6572945	Chandra T, Stackhouse R, Kidd VJ, Woo SL: Isolation and sequence characterization of a cDNA clone of human antithrombin III. Proc Natl Acad Sci U S A. 1983 Apr;80(7):1845-8.
6582486	Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N: Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci U S A. 1984 Jan;81(2):289-93.
6693405	Blackburn MN, Smith RL, Carson J, Sibley CC: The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence. J Biol Chem. 1984 Jan 25;259(2):939-41.
7238875	Bjork I, Danielsson A, Fenton JW, Jornvall: The site in human antithrombin for functional proteolytic cleavage by human thrombin. FEBS Lett. 1981 Apr 20;126(2):257-60.
7656006	Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJ, Grootenhuis PD, Hol WG: The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol. 1994 Jan;1(1):48-54.
7749926	Stein PE, Carrell RW: What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol. 1995 Feb;2(2):96-113.
7832187	Okajima K, Abe H, Wagatsuma M, Okabe H, Takatsuki K: Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin. Am J Hematol. 1995 Jan;48(1):12-8.
7878627	Emmerich J, Chadeuf G, Alhenc-Gelas M, Gouault-Heilman M, Toulon P, Fiessinger JN, Aiach M: Molecular basis of antithrombin type I deficiency: the first large in-frame deletion and two novel mutations in exon 6. Thromb Haemost. 1994 Oct;72(4):534-9.
7959685	Millar DS, Wacey AI, Ribando J, Melissari E, Laursen B, Woods P, Kakkar VV, Cooper DN: Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Hum Genet. 1994 Nov;94(5):509-12.
7989582	Bruce D, Perry DJ, Borg JY, Carrell RW, Wardell MR: Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp) J Clin Invest. 1994 Dec;94(6):2265-74.
7994035	van Boven HH, Olds RJ, Thein SL, Reitsma PH, Lane DA, Briet E, Vandenbroucke JP, Rosendaal FR: Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families. Blood. 1994 Dec 15;84(12):4209-13.
8087553	Carrell RW, Stein PE, Fermi G, Wardell MR: Biological implications of a 3 A structure of dimeric antithrombin. Structure. 1994 Apr 15;2(4):257-70.
8236149	Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, Blajchman M, Perry D, Emmerich J, Aiach M: Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1993 Aug 2;70(2):361-9.
8274732	Jochmans K, Lissens W, Vervoort R, Peeters S, De Waele M, Liebaers I: Antithrombin-Gly 424 Arg: a novel point mutation responsible for type 1 antithrombin deficiency and neonatal thrombosis. Blood. 1994 Jan 1;83(1):146-51.
8443391	Okajima K, Abe H, Maeda S, Motomura M, Tsujihata M, Nagataki S, Okabe H, Takatsuki K: Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Blood. 1993 Mar 1;81(5):1300-5.
8476848	Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL: Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry. 1993 Apr 27;32(16):4216-24.
8486379	Olds RJ, Lane DA, Beresford CH, Abildgaard U, Hughes PM, Thein SL: A recurrent deletion in the antithrombin gene, AT106-108(-6 bp), identified by DNA heteroduplex detection. Genomics. 1993 Apr;16(1):298-9.
8664906	Perry DJ, Carrell RW: Molecular genetics of human antithrombin deficiency. Hum Mutat. 1996;7(1):7-22.
9067613	Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR: The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol. 1997 Feb 28;266(3):601-9.
9761669	Skinner R, Chang WS, Jin L, Pei X, Huntington JA, Abrahams JP, Carrell RW, Lomas DA: Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin. J Mol Biol. 1998;283(1):9-14.
9845533	Fitches AC, Appleby R, Lane DA, De Stefano V, Leone G, Olds RJ: Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood. 1998 Dec 15;92(12):4671-6.

# Drug_Target_1_HGNC_ID:
HGNC:775

# Drug_Target_1_HPRD_ID:
00122

# Drug_Target_1_ID:
309

# Drug_Target_1_Locus:
1q23-q25.1

# Drug_Target_1_Molecular_Weight:
52603

# Drug_Target_1_Name:
Antithrombin-III

# Drug_Target_1_Number_of_Residues:
464

# Drug_Target_1_PDB_ID:
1JVQ

# Drug_Target_1_Pathway:
Ardeparin Pathway	SMP00275
Enoxaparin Pathway	SMP00272
Fondaparinux Pathway	SMP00273
Heparin Pathway	SMP00274

# Drug_Target_1_Pfam_Domain_Function:
PF00079	Serpin

# Drug_Target_1_Protein_Sequence:
>Antithrombin-III precursor
MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEK
KATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFA
MTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFG
DKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAIN
ELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQ
VLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDG
FSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAV
VIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-32

# Drug_Target_1_Specific_Function:
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin

# Drug_Target_1_SwissProt_ID:
P01008

# Drug_Target_1_SwissProt_Name:
ANT3_HUMAN

# Drug_Target_1_Synonyms:
ATIII
Antithrombin-III precursor

# Drug_Target_1_Theoretical_pI:
6.68

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
19888514	Schlesinger M, Simonis D, Schmitz P, Fritzsche J, Bendas G: Binding between heparin and the integrin VLA-4. Thromb Haemost. 2009 Nov;102(5):816-22.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ITGA4

# Drug_Target_2_GenBank_ID_Gene:
X16983

# Drug_Target_2_GenBank_ID_Protein:
33946

# Drug_Target_2_GeneCard_ID:
ITGA4

# Drug_Target_2_Gene_Name:
ITGA4

# Drug_Target_2_Gene_Sequence:
>3117 bp
ATGTTCCCCACCGAGAGCGCATGGCTTGGGAAGCGAGGCGCGAACCCGGGCCCCGAAGCC
GCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTAC
AACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTAC
TCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCC
AACTGGCTCGCCAACGCTTCAGTGATCAATCCCGGGGCGATTTACAGATGCAGGATCGGA
AAGAATCCCGGCCAGACGTGCGAACAGCTCCAGCTGGGTAGCCCTAATGGAGAACCTTGT
GGAAAGACTTGTTTGGAAGAGAGAGACAATCAGTGGTTGGGGGTCACACTTTCCAGACAG
CCAGGAGAAAATGGATCCATCGTGACTTGTGGGCATAGATGGAAAAATATATTTTACATA
AAGAATGAAAATAAGCTCCCCACTGGTGGTTGCTATGGAGTGCCCCCTGATTTACGAACA
GAACTGAGTAAAAGAATAGCTCCGTGTTATCAAGATTATGTGAAAAAATTTGGAGAAAAT
TTTGCATCATGTCAAGCTGGAATATCCAGTTTTTACACAAAGGATTTAATTGTGATGGGG
GCCCCAGGATCATCTTACTGGACTGGCTCTCTTTTTGTCTACAATATAACTACAAATAAA
TACAAGGCTTTTTTAGACAAACAAAATCAAGTAAAATTTGGAAGTTATTTAGGATATTCA
GTCGGAGCTGGTCATTTTCGGAGCCAGCATACTACCGAAGTAGTCGGAGGAGCTCCTCAA
CATGAGCAGATTGGTAAGGCATATATATTCAGCATTGATGAAAAAGAACTAAATATCTTA
CATGAAATGAAAGGTAAAAAGCTTGGATCGTACTTTGGAGCTTCTGTCTGTGCTGTGGAC
CTCAATGCAGATGGCTTCTCAGATCTGCTCGTGGGAGCACCCATGCAGAGCACCATCAGA
GAGGAAGGAAGAGTGTTTGTGTACATCAACTCTGGCTCGGGAGCAGTAATGAATGCAATG
GAAACAAACCTCGTTGGAAGTGACAAATATGCTGCAAGATTTGGGGAATCTATAGTTAAT
CTTGGCGACATTGACAATGATGGCTTTGAAGATGTTGCTATCGGAGCTCCACAAGAAGAT
GACTTGCAAGGTGCTATTTATATTTACAATGGCCGTGCAGATGGGATCTCGTCAACCTTC
TCACAGAGAATTGAAGGACTTCAGATCAGCAAATCGTTAAGTATGTTTGGACAGTCTATA
TCAGGACAAATTGATGCAGATAATAATGGCTATGTAGATGTAGCAGTTGGTGCTTTTCGG
TCTGATTCTGCTGTCTTGCTAAGGACAAGACCTGTAGTAATTGTTGACGCTTCTTTAAGC
CACCCTGAGTCAGTAAATAGAACGAAATTTGACTGTGTTGAAAATGGATGGCCTTCTGTG
TGCATAGATCTAACACTTTGTTTCTCATATAAGGGCAAGGAAGTTCCAGGTTACATTGTT
TTGTTTTATAACATGAGTTTGGATGTGAACAGAAAGGCAGAGTCTCCACCAAGATTCTAT
TTCTCTTCTAATGGAACTTCTGACGTGATTACAGGAAGCATACAGGTGTCCAGCAGAGAA
GCTAACTGTAGAACACATCAAGCATTTATGCGGAAAGATGTGCGGGACATCCTCACCCCA
ATTCAGATTGAAGCTGCTTACCACCTTGGTCCTCATGTCATCAGTAAACGAAGTACAGAG
GAATTCCCACCACTTCAGCCAATTCTTCAGCAGAAGAAAGAAAAAGACATAATGAAAAAA
ACAATAAACTTTGCAAGGTTTTGTGCCCATGAAAATTGTTCTGCTGATTTACAGGTTTCT
GCAAAGATTGGGTTTTTGAAGCCCCATGAAAATAAAACATATCTTGCTGTTGGGAGTATG
AAGACATTGATGTTGAATGTGTCCTTGTTTAATGCTGGAGATGATGCATATGAAACGACT
CTACATGTCAAACTACCCGTGGGTCTTTATTTCATTAAGATTTTAGAGCTGGAAGAGAAG
CAAATAAACTGTGAAGTCACAGATAACTCTGGCGTGGTACAACTTGACTGCAGTATTGGC
TATATATATGTAGATCATCTCTCAAGGATAGATATTAGCTTTCTCCTGGATGTGAGCTCA
CTCAGCAGAGCGGAAGAGGACCTCAGTATCACAGTGCATGCTACCTGTGAAAATGAAGAG
GAAATGGACAATCTAAAGCACAGCAGAGTGACTGTAGCAATACCTTTAAAATATGAGGTT
AAGCTGACTGTTCATGGGTTTGTAAACCCAACTTCATTTGTGTATGGATCAAATGATGAA
AATGAGCCTGAAACGTGCATGGTGGAGAAAATGAACTTAACTTTCCATGTTATCAACACT
GGCAATAGTATGGCTCCCAATGTTAGTGTGGAAATAATGGTACCAAATTCTTTTAGCCCC
CAAACTGATAAGCTGTTCAACATTTTGGATGTCCAGACTACTACTGGAGAATGCCACTTT
GAAAATTATCAAAGAGTGTGTGCATTAGAGCAGCAAAAGAGTGCAATGCAGACCTTGAAA
GGCATAGTCCGGTTCTTGTCCAAGACTGATAAGAGGCTATTGTACTGCATAAAAGCTGAT
CCACATTGTTTAAATTTCTTGTGTAATTTTGGGAAAATGGAAAGTGGAAAAGAAGCCAGT
GTTCATATCCAACTGGAAGGCCGGCCATCCATTTTAGAAATGGATGAGACTTCAGCACTC
AAGTTTGAAATAAGAGCAACAGGTTTTCCAGAGCCAAATCCAAGAGTAATTGAACTAAAC
AAGGATGAGAATGTTGCGCATGTTCTACTGGAAGGACTACATCATCAAAGACCCAAACGT
TATTTCACCATAGTGATTATTTCAAGTAGCTTGCTACTTGGACTTATTGTACTTCTGTTG
ATCTCATATGTTATGTGGAAGGCTGGCTTCTTTAAAAGACAATACAAATCTATCCTACAA
GAAGAAAACAGAAGAGACAGTTGGAGTTATATCAACAGTAAAAGCAATGATGATTAA

# Drug_Target_2_General_Function:
Involved in fibronectin binding

# Drug_Target_2_General_References:
11533025	Han J, Liu S, Rose DM, Schlaepfer DD, McDonald H, Ginsberg MH: Phosphorylation of the integrin alpha 4 cytoplasmic domain regulates paxillin binding. J Biol Chem. 2001 Nov 2;276(44):40903-9. Epub 2001 Aug 30.
1551405	Rubio M, Nueda A, Vara A, Corbi Lopez AL: A single mRNA encodes the alpha 150 and alpha 80/70 forms of the alpha subunit of VLA4. Eur J Immunol. 1992 Apr;22(4):1099-102.
1730718	Teixido J, Parker CM, Kassner PD, Hemler ME: Functional and structural analysis of VLA-4 integrin alpha 4 subunit cleavage. J Biol Chem. 1992 Jan 25;267(3):1786-91.
2034655	Rosen GD, Birkenmeier TM, Dean DC: Characterization of the alpha 4 integrin gene promoter. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4094-8.
2788572	Takada Y, Elices MJ, Crouse C, Hemler ME: The primary structure of the alpha 4 subunit of VLA-4: homology to other integrins and a possible cell-cell adhesion function. EMBO J. 1989 May;8(5):1361-8.
3033641	Takada Y, Strominger JL, Hemler ME: The very late antigen family of heterodimers is part of a superfamily of molecules involved in adhesion and embryogenesis. Proc Natl Acad Sci U S A. 1987 May;84(10):3239-43.
8643114	Szabo M, McIntyre BW: Identification of two variants of the human integrin alpha 4 subunit. Mol Immunol. 1995 Dec;32(17-18):1453-4.

# Drug_Target_2_HGNC_ID:
HGNC:6140

# Drug_Target_2_HPRD_ID:
01894

# Drug_Target_2_ID:
647

# Drug_Target_2_Locus:
2q31.3

# Drug_Target_2_Molecular_Weight:
115334

# Drug_Target_2_Name:
Integrin alpha-4

# Drug_Target_2_Number_of_Residues:
1038

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00357	Integrin_alpha
PF01839	FG-GAP
PF08441	Integrin_alpha2

# Drug_Target_2_Protein_Sequence:
>Integrin alpha-4 precursor
MFPTESAWLGKRGANPGPEAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGY
SVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPC
GKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRT
ELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNK
YKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNIL
HEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAM
ETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTF
SQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLS
HPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFY
FSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTE
EFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSM
KTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIG
YIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEV
KLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSP
QTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKAD
PHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELN
KDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQ
EENRRDSWSYINSKSNDD

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-39

# Drug_Target_2_Specific_Function:
Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha- 4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha- 4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells

# Drug_Target_2_SwissProt_ID:
P13612

# Drug_Target_2_SwissProt_Name:
ITA4_HUMAN

# Drug_Target_2_Synonyms:
CD49d antigen
Integrin alpha-4 precursor
Integrin alpha-IV
VLA-4

# Drug_Target_2_Theoretical_pI:
6.32

# Drug_Target_2_Transmembrane_Regions:
984-1007

# Drug_Target_3_Cellular_Location:
Secreted protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
18991783	Koo CY, Sen YP, Bay BH, Yip GW: Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov. 2008 Nov;3(3):151-8.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
CXCL12

# Drug_Target_3_GenBank_ID_Gene:
U16752

# Drug_Target_3_GenBank_ID_Protein:
571508

# Drug_Target_3_GeneCard_ID:
CXCL12

# Drug_Target_3_Gene_Name:
CXCL12

# Drug_Target_3_Gene_Sequence:
>282 bp
ATGAACGCCAAGGTCGTGGTCGTGCTGGTCCTCGTGCTGACCGCGCTCTGCCTCAGCGAC
GGGAAGCCCGTCAGCCTGAGCTACAGATGCCCATGCCGATTCTTCGAAAGCCATGTTGCC
AGAGCCAACGTCAAGCATCTCAAAATTCTCAACACTCCAAACTGTGCCCTTCAGATTGTA
GCCCGGCTGAAGAACAACAACAGACAAGTGTGCATTGACCCGAAGCTAAAGTGGATTCAG
GAGTACCTGGAGAAAGCTTTAAACAAGAGGTTCAAGATGTGA

# Drug_Target_3_General_Function:
Involved in cytokine activity

# Drug_Target_3_General_References:
7490086	Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, Honjo T: Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 1995 Aug 10;28(3):495-500.
9384579	Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD, Clark-Lewis I: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 1997 Dec 1;16(23):6996-7007.
9618518	Dealwis C, Fernandez EJ, Thompson DA, Simon RJ, Siani MA, Lolis E: Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1alpha, a potent ligand for the HIV-1 "fusin" coreceptor. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6941-6.

# Drug_Target_3_HGNC_ID:
HGNC:10672

# Drug_Target_3_HPRD_ID:
02904

# Drug_Target_3_ID:
2020

# Drug_Target_3_Locus:
10q11.1

# Drug_Target_3_Molecular_Weight:
10666

# Drug_Target_3_Name:
Stromal cell-derived factor 1

# Drug_Target_3_Number_of_Residues:
93

# Drug_Target_3_PDB_ID:
1VMC

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00048	IL8

# Drug_Target_3_Protein_Sequence:
>Stromal cell-derived factor 1 precursor
MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV
ARLKNNNRQVCIDPKLKWIQEYLEKALNKRFKM

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-21

# Drug_Target_3_Specific_Function:
Chemoattractant active on T-lymphocytes, monocytes, but not neutrophils. SDF-1-beta(3-72) and SDF-1-alpha(3-67) show a reduced chemotactic activity. Binding to cell surface proteoglycans seems to inhibit formation of SDF-1-alpha(3-67) and thus to preserve activity on local sites

# Drug_Target_3_SwissProt_ID:
P48061

# Drug_Target_3_SwissProt_Name:
SDF1_HUMAN

# Drug_Target_3_Synonyms:
CXCL12
PBSF
Pre-B cell growth-stimulating factor
SDF-1
Stromal cell-derived factor 1 precursor
hIRH

# Drug_Target_3_Theoretical_pI:
10.54

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB06822
